BMO Capital Markets has kicked off coverage of Trevi Therapeutics with an Outperform rating and a $36 price target, a move that underscores growing institutional confidence in the US-based biotech firm. The stock, which trades on the Nasdaq, saw modest gains in pre-market activity following the announcement, though broader market moves remained subdued as investors awaited earnings season data.
Trevi Therapeutics is primarily known for its lead candidate, nalbuphine ER, which is being developed to treat chronic cough in patients with idiopathic pulmonary fibrosis and pruritus associated with prurigo nodularis. The company has reported positive Phase 2b/3 data for chronic cough, positioning it as a potential first-in-class therapy in a space with limited approved options. BMO's analyst noted that the risk-reward profile is attractive given the unmet medical need and the size of the addressable market.
For UK investors, the news serves as a reminder of the cross-border opportunities in biotech, though direct exposure remains limited for most FTSE 100 or 250 portfolios. The FTSE 100 edged up 0.2% to 8,210 points on Monday, with the healthcare sector broadly flat. AstraZeneca and GSK, two heavyweight pharma stocks on the index, were unchanged as market focus shifted to upcoming US Federal Reserve interest rate decisions.
Analysts at other houses have also taken note of Trevi's progress. The company's late-stage trials are expected to read out further data in the coming months, which could be a catalyst for the stock. However, investors should be aware that biotech stocks carry significant volatility, and regulatory outcomes remain uncertain.
The broader context for UK pension holders is that while Trevi is not a domestic stock, the performance of US biotech indices can influence global sentiment and sector-specific exchange-traded funds. The Nasdaq Biotechnology Index has risen 6% year-to-date, outperforming the wider market, as investors seek growth in innovative therapies.